ABCA1-Targeting Polypeptide for NAFLD and Atherosclerosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for nonalcoholic fatty liver disease (NAFLD) are limited, and statins, while effective for cardiovascular disease, come with significant adverse effects and limited efficacy, necessitating alternative therapeutic approaches to manage lipid accumulation and atherosclerosis.
Innovation Solution
A first-in-class polypeptide comprising a specific amino acid sequence, potentially modified with stearic acid, is administered to inhibit ABCA1 to reduce lipid accumulation and inflammation, thereby treating NAFLD and atherosclerosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If statins are used to reduce LDL cholesterol, then cardiovascular disease risk is reduced, but adverse effects such as diabetes, cognitive loss, and hepatic dysfunction increase
Solution Approach 1:
The patent extracts and targets the specific molecular mechanism (ABCA1 transporter) responsible for cholesterol efflux, rather than using broad HMG-CoA reductase inhibition. This selective approach reduces off-target adverse effects while maintaining cardiovascular protection benefits.
Solution Approach 2:
The invention changes the therapeutic parameter from general cholesterol synthesis inhibition to specific ABCA1-mediated cholesterol efflux enhancement, using a polypeptide with optimized amino acid sequence to achieve selective modulation of the target pathway.
2Reliability
If statins are used to decrease LDL cholesterol, then atherosclerosis risk is reduced, but efficacy is limited to less than 30% protection
Solution Approach 1:
Instead of inhibiting cholesterol synthesis upstream (statin approach), the patent activates downstream cholesterol efflux through ABCA1, reversing the therapeutic strategy to achieve more effective atherosclerosis protection.
Solution Approach 2:
The patent introduces an intermediary polypeptide that specifically binds to and activates ABCA1, serving as a mediator between the therapeutic agent and the cholesterol efflux pathway, thereby enhancing protective effects.
3Reliability
If lifestyle modification with weight loss is implemented, then NAFLD symptoms improve, but compliance and long-term sustainability are difficult to maintain
Solution Approach 1:
The polypeptide therapy enables the body's own ABCA1 system to perform cholesterol efflux function, allowing the therapeutic effect to be self-sustaining through endogenous mechanism activation rather than requiring continuous external lifestyle intervention.
4Reliability
If ABCA1 activity is enhanced to increase cholesterol efflux, then lipid accumulation in hepatocytes is reduced, but the mechanism is not yet fully understood or optimized
Solution Approach 1:
The patent segments the ABCA1 protein into specific amino acid sequences (peptides) that can be independently synthesized and tested, allowing systematic optimization of each segment's binding and activation capability.
Solution Approach 2:
The invention creates composite polypeptide structures combining specific amino acid sequences with potential modifications to optimize ABCA1 binding affinity and cholesterol efflux activation, integrating multiple functional elements into a single therapeutic agent.
Data Source
AI summary
The present disclosure provides a polypeptide and application thereof. The polypeptide comprises a peptide fragment composed of 16-23 consecutive amino acids in an amino acid sequence represented by SEQ ID NO: 1; or the polypeptide comprises a polypeptide fragment which consists of 16-23 consecutive amino acids of the amino acid sequence of SEQ ID NO: 1 in the opposite direction of the peptide sequence (reverse peptide). The polypeptide can be used to mitigate metabolic syndrome, achieve weight loss, prevent and treat nonalcoholic fatty liver diseases and cardiovascular diseases.